Lexicon Pharma (LXRX) Misses Q2 EPS by 4c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq rise in choppy trading as tech steadies, Micron results in focus
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Lexicon Pharma (LXRX) to Resume Trading at 7:45 a.m.
July 30, 2020 7:42 AM EDTLexicon Pharma (NASDAQ: LXRX) to Resume Trading at 7:45 a.m.
... MoreLexicon Pharma (LXRX) Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program
July 30, 2020 7:42 AM EDTLexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it is realigning its business around its research and development assets, with a focus on its LX9211 neuropathic pain program, now in Phase 2 clinical development. In that regard:
Initiation of Phase 2 Clinical Development of LX9211. Lexicon has initiated patient screening in RELIEF-DPN-1, a Phase 2 randomized, placebo-controlled,... More
Lexicon Pharma (LXRX) Announces Sale of XERMELO for $159 Million
July 30, 2020 7:11 AM EDTLexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and TerSera Therapeutics LLC announced today that they have entered into an asset purchase and sale agreement for the sale to TerSera of Lexicons rights, title and interest in XERMELO® (telotristat ethyl).
Pursuant to the terms of the agreement, TerSera will pay Lexicon approximately $159 million in cash at closing, which includes a $155 million upfront... More
Lexicon Pharma (LXRX) Halted, News Pending
July 30, 2020 6:58 AM EDTLexicon Pharma (NASDAQ: LXRX) Halted, News Pending
... More